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Analysis of a nuclear family with three affected offspring identiﬁed an autosomal-recessive form of spondyloepimetaphyseal dysplasia
characterized by severe short stature and a unique constellation of radiographic ﬁndings. Homozygosity for a haplotype that was iden-
tical by descent between two of the affected individuals identiﬁed a locus for the disease gene within a 17.4 Mb interval on chromosome
15, a region containing 296 genes. These genes were assessed and ranked by cartilage selectivity with whole-genome microarray data,
revealing only two genes, encoding aggrecan and chondroitin sulfate proteoglycan 4, that were selectively expressed in cartilage.
Sequence analysis of aggrecan complementary DNA from an affected individual revealed homozygosity for a missense mutation
(c.6799G / A) that predicts a p.D2267N amino acid substitution in the C-type lectin domain within the G3 domain of aggrecan.
The D2267 residue is predicted to coordinate binding of a calcium ion, which inﬂuences the conformational binding loops of the
C-type lectin domain that mediate interactions with tenascins and other extracellular-matrix proteins. Expression of the normal and
mutant G3 domains in mammalian cells showed that the mutation created a functional N-glycosylation site but did not adversely affect
protein trafﬁcking and secretion. Surface-plasmon-resonance studies showed that the mutation inﬂuenced the binding and kinetics of
the interactions between the aggrecan G3 domain and tenascin-C. These ﬁndings identify an autosomal-recessive skeletal dysplasia and
a signiﬁcant role for the aggrecan C-type lectin domain in regulating endochondral ossiﬁcation and, thereby, height.Many of the determinants of normal human growth have
been deﬁned by studying short-stature disorders, the skel-
etal dysplasias.1 Frequently, the disease genes in these
disorders have identiﬁed molecules essential for normal
skeletal development as well as functional domains within
the proteins they encode. The functions of the skeletal-
dysplasia disease genes are as diverse as the conditions
with which they are associated, and the gene products
include regulatory molecules, cytoskeletal proteins, cen-
trosomal proteins, and extracellular-matrix structural
proteins along with their posttranslational modiﬁers. The
disease genes are often selectively expressed in chondro-
osseous tissues, or they can be more widely expressed
with a greater effect on cartilage and/or bone resulting
from the distinctive biology of skeletal tissues. Together,
these genes deﬁne the size and shape of the craniofacial,
axial, and appendicular skeletal elements, the extent of
linear growth, and the long-term stability of cartilage and
bone.
Figure 1 shows the pedigree of a family, studied under an
institutional review board-approved protocol, with
a distinctive skeletal-dysplasia phenotype. The three
affected individuals were initially ascertained as young
children and shared a consistent set of phenotypic ﬁnd-
ings that were present at all ages (Table 1). Craniofacial
abnormalities included relative macrocephaly, severe mid-72 The American Journal of Human Genetics 84, 72–79, January 9, 2face hypoplasia with almost absent nasal cartilage, relative
prognathism, and slightly low-set, posteriorly rotated ears
(Figure 1). They had short necks and barrel chests and
exhibited amild lumbar lordosis. Their extremities showed
rhizomelia and mesomelia with no bowing of any
segment. Hand ﬁndings included signiﬁcant brachydac-
tyly with short, broad thumbs, horizontal nails, and tele-
scoping interphalangeal joints. Their childhoods were
only complicated by extreme short stature, without ortho-
pedic or other systemic complications. Radiographs
(Figure 2) revealed ﬁndings consistent with a previously
undescribed form of spondyloepimetaphyseal dysplasia
(SEMD). Long bones exhibited generalized irregular epiph-
yses with widened metaphyses, especially at the knees.
Spinal abnormalities included signiﬁcantly ﬂattened verte-
bral bodies (platyspondyly) and multiple cervical-vertebral
clefts. Hand radiographs showed proportionate brachydac-
tyly with accessory carpal ossiﬁcation centers.
At the time of the most recent examination, their ages
ranged from 16–26 years of age. They all exhibited extreme
short stature, 26–28 in (66–71 cm) total height, with
upper/lower (U/L) segment ratios ranging from 1.1–1.2.
Their clinical ﬁndings were largely similar to those
observed in childhood, except that one of the affected
individuals complained of bronchospasm that worsened
with respiratory infections, and he had a hoarse voice.1Medical Genetics Institute, Steven Spielberg Building, Cedars-Sinai Medical Center, 8723 Alden Drive, Los Angeles, CA 90048, USA; 2Department of
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Figure 1. Clinical Phenotype
(A) Pedigree. Filled symbols identify affected individuals.
(B) In the top left image, the back row from left to right shows II-1 (23 years old [yo]) and I-I (58 yo), respectively, and the front row
from left to right shows II-2 (19 yo), II-3 (16 yo), and II-4 (26 yo), respectively. Note the relative macrocephaly and lordosis in II-2 in
the top right image, the telescoping fingers of II-3 in the lower left image, and the midface hypoplasia, relative prognathism, and low-set
ears in II-4 in the lower right image.The parents both originated in a small village in the state of
Zacatecas in Mexico, but consanguinity was denied. The
mother and father were 150 cm and 152 cm tall, respec-
tively. A half sister (II-5) was 150 cm tall. The parents and
half sibling were proportionate and had neither dysmor-
phic facial ﬁndings nor brachydactyly (normal metacarpo-Thephalangeal proﬁles; data not shown). They denied any
complaints of joint pain or limitations and had no difﬁ-
culty with physical activities. An unaffected full sibling
(Figure 1, II-1) was 178 cm tall.
To assess thegenetic relationshipbetween theparents,we
comparedwhole-genome single-nucleotide polymorphismAmerican Journal of Human Genetics 84, 72–79, January 9, 2009 73
(SNP) data. This analysis revealed several 10–20 cM blocks
of shared alleles (data not shown), implying an ancestral
relationship and supporting the hypothesis that their
affected childrenmight be homozygous for the samemuta-
tion, identical by descent. We tested this hypothesis by
comparing whole-genome SNP genotypes between two of
the three affected individuals to look for regions of shared
homozygosity. A single interval, located between 72.0 and
89.4 Mb on chromosome 15, met this requirement
(Figure 3), suggesting that the phenotype was indeed reces-
sively inherited, that themutationwaswithin a gene in this
interval, and that the affected individuals should be homo-
zygous for the mutation. The unaffected sibling, II-1, was
not homozygous for this interval.
The interval on chromosome 15 contained 193 anno-
tated and 103 unannotated genes. To prioritize the genes
for mutation analysis, we used whole-genome microarray
data to determine the cartilage selectivity of gene expres-
sion2 under the hypothesis that the cartilage-speciﬁc
nature of the phenotype would be consistent with a muta-
tion in a gene selectively expressed in the target tissue.
There were two highly cartilage-selective genes in the
interval (Figure 4), chondroitin sulfate proteoglycan 4
(CSPG4 [MIM 601172]) and aggrecan (ACAN [MIM
155760]). These were the only genes in the interval that
were highly expressed in cartilage (at least 5-fold higher
in cartilage than in the noncartilage tissues) and that
were not expressed in the noncartilage tissues (deﬁned
by an analog of coefﬁcient of variation of below 1 in the
noncartilage tissues).
Aggrecan is amember of the lectican family of proteogly-
cans and is among themost abundant proteoglycans in the
cartilage extracellular matrix. Mutations in the ACAN gene
Table 1. Summary of the Clinical Findings among the Three
Affected Individuals
Clinical Findings II-4 II-2 II-3
Height 26 in/66 cm 28 in/68 cm 27 in/71 cm
U/L segment ratios 1.1 1.2 1.2








Relative prognathism þ þ þ
Short neck þ þ þ
Hoarse voice  þ þ
Bronchospasm  þ 
Barrel-shaped chest þ þ þ
Lumbar lordosis þ þ þ
Rhizomelia þ þ þ
Mesomelia þ þ þ
Brachydactyly
(hand length)
7.5 in/18.5 cm 8 in/20 cm 8 in/20 cm
Broad thumbs þ þ þ
Horizontal nail beds þ þ þ
Joint laxity, especially
hands
þ þ þ74 The American Journal of Human Genetics 84, 72–79, January 9, 2have been identiﬁed in skeletal-dysplasia phenotypes in
humans3 and other species,4–6 so the coding region of
ACAN was tested for mutations (for primer sequences,
please see Table S1, available online). Sequence analysis
of complementary DNA (cDNA) from II-2, derived from
RNA isolated from cultured skin ﬁbroblasts, revealed
homozygosity for a point mutation (NM_013227.2:
c.6799G / A) that predicts a p.D2267N substitution in
the C-type lectin domain (CLD) within the G3 globular
domain of the protein (Figure 5). The sequence change
was conﬁrmed by sequence analysis of ampliﬁed genomic
DNA, and the other two affected individuals were also
homozygous for this change. The parents and half sibling
(II-5) were heterozygous for the sequence change, whereas
II-1 did not inherit the putative mutant allele. The
sequence change was not found among 240 ethnically
matched control chromosomes, indicating that it is not
a common polymorphism in the population and consis-
tent with the D2267N change causing the disorder.
The D2267 aspartic-acid residue exhibits a very high
degree of conservation throughout evolution. It has been
identiﬁed in all known aggrecan orthologs, including
those in mouse, chick, zebraﬁsh, and sea squirt (Figure 5).
Thus, this residue has been completely conserved since at
least 550 million years ago, a time when sea squirts and
vertebrates shared a common ancestor,7 suggesting func-
tional signiﬁcance. Brevican, versican, and neurocan, three
othermembers of the lectican family of proteoglycans, also
contain this conserved aspartic-acid residue in their G3
globular domains, supporting a functionally important
role in paralogous proteins. The evolutionary conservation
also suggests that the sequence change causes the disorder.
The crystal structure of the CLD of rat aggrecan com-
plexed with the ﬁbronectin type III repeats of tenascin-R8
(Research Collaboratory for Structural Bioinformatics
Protein Data Bank structure 1TDQ) also suggests a func-
tional role for D2267. The structure shows that the aggre-
can-tenascin interaction is highly calcium-ion dependent,
requiring coordination of three calcium ions in the CLD.
Coordination of calcium-1 requires ﬁve amino acids
including D2267, the residue found to be mutated in this
family (known as Asp64 in Lundell et al.8). According to
the structure, the calcium ions function as an integral
part of the CLD coordination loops, ordering these regions
such that they mediate speciﬁc interactions with ﬁbro-
nectin type III repeats 4 and 5 of tenascin-R. These ﬁndings
suggest that the mutation might disrupt interactions
between aggrecan and tenascin or, perhaps, other matrix
molecules.
To determine the effect of the D2267N mutation on the
secretion and interactions of the CLD of aggrecan, we ex-
pressed a cDNA fragment containing the entire CLD in
mammalian cells and puriﬁed the recombinant protein.
In brief, we performed PCR-based site-directed mutagen-
esis on a wild-type human aggrecan G3 domain cDNA
clone to introduce the D2267N mutation. We subcloned




Figure 2. Radiographic Phenotype
(A), (B), and (D)–(F) are from II-4 at 9.5 yo, and (C) is from II-2 at 1 yo. Radiographs show (A) mild scoliosis, (B) platyspondyly, (C) clefts
of the cervical-vertebral bodies (indicated by arrow), (D) shortening of the limbs with small irregular epiphyses and widened metaphyses,
(E) an enlarged skull with midface hypoplasia, and (F) brachydactyly with extra carpal ossification centers.to contain a signal sequence and a carboxyl-terminal His
tag with a proximal enterokinase cleavage site.9 The puri-
ﬁed DNA was then transfected into 293-EBNA cells
(human embryonic kidney cells; Invitrogen) with Lipofect-
AMINE 2000 reagent (Invitrogen). Transfected cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% fetal calf serum, and, after 24 hr in culture, the
transfected cells were selected by the addition of Hygrom-
ycin B (50 mg/ml). After cell conﬂuency, the culture
medium was replaced with serum-free medium, and the
cells were incubated in this medium for a further 48 hr
before the conditioned medium was collected. SDS-PAGE
and western blotting were used for analyzing the cell-
culture media and cell lysates of the wild-type and mutant
cell lines (Figure 6A). Two recombinant forms of both WT
and mutant (glycosylated) aggrecan G3 domain were used
in these studies, one containing the epidermal growth
factor (EGF) repeats (long form) that have been shown to
enhance tenascin-C binding,10 and one without the EGF
modules (short form). Analysis of the media and cell-lysate
samples conﬁrmed that the WT proteins were efﬁciently
secreted, as has previously been shown for recombinantThe AACAN protein fragments containing folded globular
motifs.10 The mutated proteins were also efﬁciently
secreted into the culture media, but they migrated more
slowly on SDS-PAGE, indicating a greater mass than the
equivalent WT proteins. The diffuse migration of the
mutated proteins suggested that they might be glycosy-
lated, a hypothesis supported by the observation that the
mutation introduced a potential N-glycosylation site
(Asn2267-Arg-Thr) into the protein sequence.
To determine whether the mutated proteins were glyco-
sylated, we ﬁrst puriﬁed the secreted WT and mutant
proteins from the conditioned medium by afﬁnity chro-
matography with the His tag. In brief, the medium was
incubated with the TALON afﬁnity column (BD Biosci-
ences) for 1 hr at 4C. Bound proteins were eluted from
the beads with 150 mM imidazole in 20 mM Tris
(pH 7.4), 300 mM NaCl. Fractions (1 ml) were collected
and analyzed by SDS-PAGE with silver staining
(Figure 6C, inset). The fractions containing the aggrecan
G3 domain were desalted with PD-10 columns (GE Health-
care) and further puriﬁed by anion exchange chromatog-
raphy on a MiniQ column with the Ettan puriﬁer HPLCmerican Journal of Human Genetics 84, 72–79, January 9, 2009 75
system (GE Healthcare). We treated 0.5 mg of recombinant
protein with 0.01 U PGNase (QA Bio) for 48 hr at 37C, and
we analyzed the treated protein product by SDS-PAGE and
western blotting. After the digestion, the diffuse D2267N
proteins appeared sharper and migrated at a similar size
to that of the WT proteins (Figure 6B). This indicated
that the secreted mutated proteins contained N-glycan
chains and suggested that aberrant glycosylation could
affect the function of the aggrecan G3 domain.
To determine the effect of the mutation on aggrecan
interactions, we used surface plasmon resonance (BIAcore
3000) to study the binding of the aggrecan G3 domain
with its known binding partner tenascin-C10 (Figure 6C).
In brief, 10 mg/ml of recombinant tenascin-C (Chemicon)
was immobilized onto a CM5 sensor chip. G3 aggrecan
scans were performed in HEPES buffer containing 2 mM
Ca2þ. All of the proteins bound to tenascin-C in the pres-
ence of 2mMCa2þ. However, themutant long form bound
at a signiﬁcantly lower level than its WT counterpart (p <
0.001, n ¼ 3). Tightly bound proteins were then dissoci-
ated by the injection of 10 mM EDTA, conﬁrming that
the binding was cation dependent. For both the long
form (p < 0.05, n ¼ 3) and the short form (p < 0.001,
n ¼ 3), the mutant aggrecan dissociated at a slower rate.
Overall, these data indicate that the D2267N mutation
does not affect secretion of the G3 domain of aggrecan
in vitro. Furthermore, the introduction of an asparagine
Figure 3. Identity by Descent Mapping
of the SEMD-Aggrecan-Type Locus
Homozygosity maps for two of the affected
siblings (II-4 and II-2) and one unaffected
sibling (II-1) from the pedigree. Each plot
shows the size of homozygous blocks for
each chromosome across the genome, in
centiMorgans, as inferred from SNP geno-
type data. The large blocks represent
recent homozygosity by descent, suggest-
ing ancestrally consanguineous parents.
The only block that fits a consanguin-
eous-recessive disease model is the chro-
mosome 15 locus, which has the identical
block of homozygosity in the affected
siblings that is not shared identically
with the unaffected sibling.
at residue 2267 created a potential
N-glycosylation recognition motif
that was glycosylated when the G3
domain was expressed in mammalian
cells. However, the pathological rele-
vance of this posttranslation modiﬁ-
cation in vivo remains undetermined.
The data presented identify the
molecular basis of a recessive form of
SEMD, here termed SEMD aggrecan
type, characterized by extreme short
stature, which results from homozygosity for a missense
mutation affecting the G3 domain of aggrecan. The
D2267N substitution affected a highly conserved residue
that contributes to the structure of the C-type lectin
domain within the G3 domain of the protein, in part by
coordinating binding of one of three calcium ions impor-
tant for its structure. The substitution also created a poten-
tial N-glycosylation site that is used in vitro. These changes
appear to inﬂuence the binding and dissociation kinetics
of interactions between the G3 domain and tenascin-C,
at least in vitro. Thus, a model for the mechanism of
disease includes the effect of the mutation on the structure
of the protein as well as the effect of introducing a novel
glycosylation site, both of which could alter the interac-
tions between aggrecan and its binding partners in the
cartilage extracellular matrix. The relative contributions
of these mechanisms cannot be distinguished by the data
presented herein.
In addition to the effect on stature, the radiographs show
clefts of the cervical-vertebral bodies and extra ossiﬁcation
centers in the carpal bones of the hands, features also
observed in diastrophic dysplasia11 (DTD [MIM 222600]).
DTD is a recessive disorder that results from reduced
activity of the universal sulfate transporter, encoded by
the SCL26A2 (MIM 606718) gene.12 The ﬁnding that
a mutation in the aggrecan gene produces similar radio-
graphic features suggests that aggrecan is an important76 The American Journal of Human Genetics 84, 72–79, January 9, 2009
Figure 4. Prioritization of Genes within the Chromosome 15 Region with Respect to their Cartilage-Selective Gene Expression
For each gene in the interval, cartilage gene expression was defined by the average expression in cartilage relative to the average expres-
sion in a panel of noncartilage tissues, indicated by pink squares with the scale on the left. The median derived coefficient of variation
(CV; shown in blue), an indirect measure of expression in noncartilage tissues, was plotted for each gene with the scale indicated on the
right. The genes in the interval were sorted by lowest CV (left) to highest CV (right). The threshold CV of 1 is marked by a horizontal red
line.target in the developing skeleton affected by the SLC26A2
mutations that produce DTD.
The carrier parents and carrier half sibling had adult
heights of approximately 150 cm, whereas a WT sibling
of the proband was 178 cm tall. This observation raises
the possibility that there is a carrier phenotype of mild,
proportionate short stature. This inference is supported
by the ﬁnding that haploinsufﬁciency for aggrecan can
lead to the mild spondyloepiphyseal dysplasia (SED) Kim-
berley phenotype,3 as well as similar phenotypes in other
species.4–6 However, because homozygosity for null muta-
tions in other species produces lethal phenotypes, and
because neither the SEMD-aggrecan-type cases nor carriers
manifest an early-onset osteoarthritis phenotype as
observed in the SED Kimberly type, the mechanisms of
disease in the two disorders are likely to be distinct.
Recently, whole-genome association studies of normal
variation in human height have implicated the ACAN
region on chromosome 15 as a regulator of height.13
Together with the data presented here, these ﬁndings
suggest that variation in the quantity and/or structure of
the aggrecan protein can produce a wide range of human
height variation.
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Figure 5. ACAN Mutation Analysis and
Evolutionary Conservation of Aspartic-
Acid Residue 2267
(A) Sequence traces derived from three
family members, indicating the single-
nucleotide change with the respective
codon highlighted (red box).
(B) Partial protein sequence of aggrecan
showing the region containing Asp2267
among aggrecan orthologs as well as paral-
ogous members of the lectican family of
proteins.
(C) Diagram of the aggrecan molecule
showing N-terminal G1 and G2 globular
domains, a highly repetitive central region
modified with keratan sulfate (KS) and
chondroitin sulfate (CS) side chains, and
the C-terminal G3 globular domain where
the mutation is located. In the expanded
diagram of the G3 domain shown below,
the red arrow indicates the location of
the mutation in the C-type lectin (CLD)
motif. Alternatively spliced epidermal
growth factor-like (EGF) and complement
regulatory protein-like (CRP) motifs are
also shown.References
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Figure 6. Biochemical Analyses of the
Wild-Type and Mutant Aggrecan G3
Proteins
(A) The effect of the D2267N mutation on
the secretion of the aggrecan G3 domain.
SDS-PAGE and western-blot analysis of
conditioned media and cell lysates from
293-EBNA cells transiently transfected
with the aggrecan G3 domain constructs
(WT and mutant). Recombinant proteins
were resolved on 4%–12% Bis-Tris gel under
reducing conditions, transferred onto nitro-
cellulose membrane, and detected by
western blotting with an antibody against
an in-frame His tag. Recombinant WT G3
domains migrated at approximately 26 kDa
for the short form and 40 kDa for the
long form, whereas the mutant proteins
migrated more slowly, with a mass of
~45 kDa for both forms. Protein samples
from cell lysates are shown in the left panel
and from the culture media in the right
panel for each form; the size of molecular
weight (MW) markers is shown on the right.
(B) N-glycanase digest of the mutated
aggrecan G3 proteins. Western-blot analysis is of purified D2267N G3 protein with (digested) or without (undigested) N-glycanase treat-
ment. The undigested D2267N protein appears as a diffuse ~45 kDa band corresponding to the glycosylated form, which is in contrast to
the digested form that becomes a sharp ~26 kDa band for the short form and ~40 kDa for the long form (similar to WT protein), indicating
that the secreted mutated proteins possess N-glycan chains.
(C) Binding analysis of recombinant aggrecan G3 domains to tenascin-C. The purity of the recombinant proteins was verified by silver
staining of SDS-PAGE gel under reducing conditions (inset). The purified proteins were then tested for their ability to bind tenascin-C.
Shown are representative sensograms (surface plasmon resonance, SPR) for WT G3 or D2267N G3 proteins at a concentration of 10 mg/ml.
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